The opportunity to acquire the business and / or assets of a leading health data and insights business providing real solutions to problems caused by metabolic disease.

Overview

Specialist data science business focused on enabling earlier identification and intervention, to improve the lives of those with metabolic disease.
An innovative range of non-invasive solutions optimised specifically for the needs of patients, Pharma, insurers and those delivering healthcare.
Concentrated on bringing efficacy and value, through clinical trials and evidence, to the digital health market.

Key features

• Comprehensive metabolic data set (from over 100 primary care practices). This equates to circa 1 million of patient data tracked over a period of 10 years.
• Applications with connectivity to more than 150 apps and devices.
• Established brand identity reflecting core values and vision.
• Numerous health and tech industry awards.
• Experienced team comprising leadership team, developers and clinical advisors.

Assets for sale

• Goodwill
• Intellectual property
• Equipment
• Customer list
• Debtors
• Order book
• Website

Summary financial information

Process

Further information can be obtained from KBL Advisory on completion of a standard non-disclosure agreement. KBL Advisory is requesting indicative offers, supported by proof of funding, by midday on 19 December 2023, with a view to completing a transaction as soon as possible thereafter. We reserve the right to close the bidding process early or extend the deadline for indicative offers without liability or advanced notice.

All correspondence in relation to this opportunity should be directed to KBL Advisory as follows:

Julie Webster                                               Steven Brown
KBL Advisory Limited                                    KBL Advisory Limited
Tel: 07344 920625                                          Tel: 07972 004258
Email: julie@kbl-advisory.com                 Email: steven.brown@kbladvisory.com